Literature DB >> 22344713

Increased expression of miR-148b in ovarian carcinoma and its clinical significance.

Hua Chang1, Xin Zhou, Zhen-Ning Wang, Yong-Xi Song, Fang Zhao, Peng Gao, Yeunpo Chiang, Hui-Mian Xu.   

Abstract

Ovarian cancer affects females worldwide and is associated with poor patient prognosis. Identification of diagnostic biomarkers and effective therapeutic targets is vital for the diagnosis and treatment of ovarian cancer. Recently, researchers have found that microRNAs play several important roles in carcinogenesis. The purpose of this study was to investigate the relationship between miR-148b expression in human ovarian cancer tissues and clinicopathological features. Seventy-seven ovarian carcinoma tissues and 17 normal ovary tissues were collected from the First Hospital of China Medical University. For quantitative detection of the expression levels of miR-148b, total RNA was extracted and then reverse transcription-polymerase chain reaction was performed. The relationship between miR-148b expression in ovarian cancer and clinicopathological features was analyzed. We found that miR-148b was overexpressed in 92.21% (71/77) of the ovarian cancer samples examined, and overexpression of miR-148b in ovarian cancer tissues was not associated with any of the clinicopathological features of patients with ovarian cancer. Taken together, miR-148b may be involved in the early stage of ovarian carcinogenesis and could be used as an efficient diagnostic biomarker.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344713     DOI: 10.3892/mmr.2012.794

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  17 in total

1.  Arsenic responsive microRNAs in vivo and their potential involvement in arsenic-induced oxidative stress.

Authors:  Xuefeng Ren; Daniel P Gaile; Zhihong Gong; Wenting Qiu; Yichen Ge; Chuanwu Zhang; Chenping Huang; Hongtao Yan; James R Olson; Terrance J Kavanagh; Hongmei Wu
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-24       Impact factor: 4.219

2.  Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker.

Authors:  Katayoun Ziari; Mojtaba Zarea; Masoumeh Gity; Amir Farshid Fayyaz; Emad Yahaghi; Ebrahim Khodaverdi Darian; Amir Masoud Hashemian
Journal:  Tumour Biol       Date:  2015-07-24

3.  MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells.

Authors:  Yinmei Dai; Wei Xia; Tao Song; Xueting Su; Jie Li; Shaohua Li; Ying Chen; Wei Wang; Hongmei Ding; Xuemei Liu; Hui Li; Qiang Zhao; Ningsheng Shao
Journal:  Nucleic Acid Ther       Date:  2012-12-03       Impact factor: 5.486

4.  miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.

Authors:  Can Shi; Zhenyu Zhang
Journal:  Tumour Biol       Date:  2015-11-12

5.  Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.

Authors:  Naeemeh Ghasemkhani; Sahar Shadvar; Yasamin Masoudi; Amir Jouya Talaei; Emad Yahaghi; Peyman Karimi Goudarzi; Ebrahim Shakiba
Journal:  Diagn Pathol       Date:  2015-09-17       Impact factor: 2.644

6.  miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.

Authors:  Farah J Nassar; Maya El Sabban; Nathalie K Zgheib; Arafat Tfayli; Fouad Boulos; Mark Jabbour; Nagi S El Saghir; Rabih Talhouk; Ali Bazarbachi; George A Calin; Rihab Nasr
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

7.  MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway.

Authors:  Jun-gang Zhang; Ying Shi; De-fei Hong; Mengqi Song; Dongsheng Huang; Chun-you Wang; Gang Zhao
Journal:  Sci Rep       Date:  2015-01-28       Impact factor: 4.379

8.  Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Authors:  Eric A Benson; Todd C Skaar; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

9.  Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues.

Authors:  Hossein Ajdarkosh; Masoomeh Dadpay; Emad Yahaghi; Elham Rostami Pirzaman; Amir Farshid Fayyaz; Ebrahim Khodaverdi Darian; Aram Mokarizadeh
Journal:  Diagn Pathol       Date:  2015-08-07       Impact factor: 2.644

10.  Integrated analysis of microRNA-target interactions with clinical outcomes for cancers.

Authors:  Je-Gun Joung; Dokyoon Kim; Su Yeon Lee; Hwa Jung Kang; Ju Han Kim
Journal:  BMC Med Genomics       Date:  2014-05-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.